Zika Response Spreads North and West in US
The presence of the Zika virus is not concentrated in Florida, although the state has more confirmed cases than any other, and the number of infected people is growing rapidly.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 202
Pfizer Earnings Fail to Impress Investors
When Pfizer reported its second-quarter financial results before the markets opened on Tuesday, investors initially did not appear impressed.
Zika Threatens Florida’s $67 Billion Tourism Revenue
On Monday, the CDC issued its first-ever travel warning for a destination inside the United States. The warning could pose a threat to Florida's tourism industry.
What to Expect From Pfizer Earnings
The upcoming earnings report will showcase what Pfizer has to offer for the second half of 2016, and potentially give some insight into what companies it may be looking to pursue next.
Can Keryx Biopharma Bounce Back From This Supply Interruption?
ThinkstockShares of Keryx Biopharmaceuticals Inc. (NASDAQ: KERX)Â sank on Monday after the company announced that there will be an interruption in the supply of Auryxia (ferric citrate) tablets due to a production-related issue converting active…
RBC Says Buy Big Biotechs Now for Possible Big 2016 Gains
Finally, concerns about biotech seem to be waning. An RBC research report notes that at the recent political conventions there was little to no mention of drug pricing.
How Biogen and Ionis Won Big (and Can Win More) From Late Stage Trial
Shares of Biogen and, especially, Ionis Pharmaceuticals made handy gains early Monday morning following favorable interim results from a late-stage trial.
How Analysts Changed Tune on Gilead After Earnings
Gilead Sciences reported its earnings on Monday of last week, and since that time there has been much analyst activity around the stock.
Analysts See Boston Scientific Turnaround Continuing to Run
When Boston Scientific reported second-quarter results Wednesday, revenues were up 10% overall, with medical and surgical product sales up nearly 30%.
Wedbush Has 3 Stocks to Buy With 70% to 140% Upside Potential
These three biotech companies not only have data that could prove to be huge, but they have been absolutely hammered over the last year and are offering aggressive accounts the best entry points in…
Why Key Analyst Sees More Headwinds for Gilead Sciences
The recent performance from Gilead Sciences has analysts and investors concerned about the future. Argus believes that the headwinds are blowing harder than the tailwinds for the company.
Why Seres Therapeutics Is Crushing Shareholders
Shares of Seres Therapeutics took an absolute dive early in Friday’s session as the company stared down the barrel of a seemingly failed mid-stage clinical trial.
How AbbVie Won Big on Earnings
AbbVie released a better-than-expected second-quarter earnings report before the markets opened on Friday.
Merck Raises EPS Outlook After Q2 Earnings
Merck reported better-than-expected second-quarter 2016 results before markets opened Friday morning.
Bristol-Myers Earnings Don’t Appear to Be Enough for Investors
Bristol-Myers Squibb released a better-than-expected second-quarter earnings report before the markets opened on Thursday.